Hong Song

Hong Song

Stanford University

H-index: 27

North America-United States

About Hong Song

Hong Song, With an exceptional h-index of 27 and a recent h-index of 17 (since 2020), a distinguished researcher at Stanford University, specializes in the field of Targeted radionuclide therapy.

His recent articles reflect a diverse array of research interests and contributions to the field:

Alpha and Beta Radiation for Theragnostics

Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer

Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu] Lu-PSMA-617 in metastatic castration-resistant …

68Ga-RM2 PET–MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial

COMBAT: A study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer.

SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.

Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT).

Assessing the clinical utility of rapid post-therapy whole-body digital SPECT/CT in evaluating early treatment response of 177Lu-PSMA-617 treatment.

Hong Song Information

University

Position

Radiology/Nuclear Medicine Resident

Citations(all)

2390

Citations(since 2020)

1035

Cited By

1717

hIndex(all)

27

hIndex(since 2020)

17

i10Index(all)

37

i10Index(since 2020)

27

Email

University Profile Page

Google Scholar

Hong Song Skills & Research Interests

Targeted radionuclide therapy

Top articles of Hong Song

Alpha and Beta Radiation for Theragnostics

2024/4/29

Hong Song
Hong Song

H-Index: 17

George Sgouros
George Sgouros

H-Index: 38

Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer

Journal of Nuclear Medicine

2024/4/25

Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu] Lu-PSMA-617 in metastatic castration-resistant …

European Journal of Nuclear Medicine and Molecular Imaging

2024/4/18

68Ga-RM2 PET–MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial

The Lancet Oncology

2024/2/26

COMBAT: A study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer.

2024/2/1

SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.

2024/2/1

Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT).

2024/2/1

Assessing the clinical utility of rapid post-therapy whole-body digital SPECT/CT in evaluating early treatment response of 177Lu-PSMA-617 treatment.

2024/2/1

Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression-free survival in …

2024/2/1

Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET

European Journal of Nuclear Medicine and Molecular Imaging

2023/11

SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting

European Journal of Nuclear Medicine and Molecular Imaging

2023/7

Assessment of the response of treatment with 18F-DCFPYL PET/CT in patients with prostate cancer

2023/6/1

A Case-Based Primer on FDG PET/CT for Imaging Cardiovascular Infections: Protocol, Interpretation, and Pitfalls.

2023/6/1

The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors

2023/1/9

Hong Song
Hong Song

H-Index: 17

64Cu-DOTATATE uptake in a pulmonary hamartoma

Clinical Nuclear Medicine

2023/1/1

Hong Song
Hong Song

H-Index: 17

Cure of Micrometastatic B-Cell Lymphoma in a SCID Mouse Model Using 213Bi-Anti-CD20 Monoclonal Antibody

Journal of Nuclear Medicine

2023/1/1

68Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate-or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment

Journal of Nuclear Medicine

2022/12/1

Biodistribution of a Mitochondrial Metabolic Tracer, [18F]F-AraG, in Healthy Volunteers

Molecular Imaging

2022/8/8

PSMA theragnostics for metastatic castration resistant prostate cancer

Translational Oncology

2022/8/1

Hong Song
Hong Song

H-Index: 17

Andrei Iagaru
Andrei Iagaru

H-Index: 32

Results of First Interim Analysis of 68Ga-NeoB and 68Ga-PSMA R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer

2022/6/1

See List of Professors in Hong Song University(Stanford University)